Research

In the Research Group Cardiovascular Remodelling we aim to uncover how the heart and blood vessels respond to injury and stress, with the goal of developing strategies to protect and repair cardiovascular tissues. Our research explores how myocardial ischemia/reperfusion, hypertrophy, and heart failure reshape the heart, and how therapies can prevent or reverse these changes. Using advanced animal models, isolated hearts, and state-of-the-art imaging, we track cellular, biochemical, and functional responses over time. Two flagship projects guide our work: studying Tenascin C in heart fibrosis and disease progression in hypertrophic cardiomyopathy, and investigating how circulating blood cells interact with the endothelium during thrombus resolution. Both projects link closely to biomarker research and implant studies, bridging mechanistic insights with translational impact.

In the Research Group Cardiovascular Biomarker we aim to harness the information carried by blood to better understand and treat cardiovascular disease. By studying platelets and tiny blood messengers called extracellular vesicles, we investigate how clots form, how inflammation shapes heart health, and how medical devices interact with blood. One project focuses on improving the safety and performance of cardiac assist devices, while another explores blood biomarkers to track disease progression and therapy response in cardiac amyloidosis. Together, these studies aim to provide actionable, personalized insights to improve patient care.

The Cardiovascular Implants Research Group is advancing the next generation of heart therapies by combining AI-driven diagnostics with smarter, blood-compatible implants. Researchers are developing digital biomarkers to guide personalized heart failure treatments while simultaneously optimizing device surfaces to reduce clotting and complications. Together, these efforts aim to make cardiovascular interventions safer, more effective, and tailored to each patient.